Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484049 | 0.89 | TP53 (0.35) | CES2CES1LMNAHPGDMAPT | |
| SCHEMBL1029779 | 0.81 | MAPT (0.46) | CES2CA1CA2NPC1RAB9A | |
| SCHEMBL67959 | 0.81 | CES2 (0.50) | CES2CES1CA1CA2BCL2L1 | |
| SCHEMBL5242548 | 0.81 | TSHR (0.52) | CES2CES1CA1CA2SMN1; SMN2 | |
| SCHEMBL5824636 | 0.79 | TPMT (0.46) | CA1CA2PTPN1 | |
| SCHEMBL2892447 | 0.79 | ALDH1A1 (0.48) | CES2CES1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20258185 | 0.79 | NOS3 (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL199868 | 0.79 | CES2 (0.48) | CES2CES1CA1CA2NPC1 | |
| SCHEMBL2318580 | 0.79 | CES2 (0.48) | CES2CES1CA1CA2RAB9A | |
| SCHEMBL24728745 | 0.78 | CES1 (0.44) | CES2CES1CA1CA2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| CN-1094929-C | Acetamide derivative, process for preparing the same, and pharmaceutical composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-11-27 | — | — | CN | disclosed |
| EP-0826673-B1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-5972946-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| CN-1186487-A | Acetamide derivatives, process for producing the same, and medicinal composition containing the same | DAINIPPON PHARMACEUTICAL CO (JP) | 1998-07-01 | — | — | CN | disclosed |
| EP-0826673-A1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5240926-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1993-08-31 | — | — | US | disclosed |
| EP-0529468-A1 | Substituted pyridyltriazines, process for their preparation, their use and intermediates | BAYER AG (DE) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | CES2 1764/4885CES1 534/4885CA1 2430/4885 |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | CES2 1095/4885CES1 2165/4885CA1 4881/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CES2 1764/4885CES1 534/4885CA1 2430/4885 |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CES2 1764/4885CES1 534/4885CA1 2430/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CES2 1764/4885CES1 534/4885CA1 2430/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CES2 4580/4885CES1 3688/4885CA1 4250/4885 |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | CES2 1764/4885CES1 534/4885CA1 2430/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | CES2 1425/4885CES1 2399/4885CA1 4879/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | CES2 4846/4885CES1 3995/4885CA1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.